Don't Routinely Recommend Repatha (Evolocumab) for High Cholesterol

December 2015

Repatha (rih-PATH-ah, evolocumab) is the first "PCSK9 inhibitor" approved for high cholesterol in Canada.

It works by preventing PCSK9...proprotein convertase subtilisin/kexin type 9...from binding and degrading liver LDL receptors. This leads to more LDL receptors...and more LDL cholesterol clearing from the blood.

Repatha can lower LDL about 60% in patients already receiving maximum statin doses.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Heart Failure Suggest Entresto for heart failure patients with persistent symptoms
Geriatrics Think of Beers Criteria as a "Warning Light" Rather Than a "Stop Sign"
Opioids More patients will need your help tapering off chronic opioids
Diabetes Diabetes patients will need your help sticking with metformin
Diabetes association between the SGLT2 inhibitor, Invokana (canagliflozin), and bone fractures
Cardiology Don't Routinely Recommend Repatha (Evolocumab) for High Cholesterol
Vitamins & Minerals Consider Supplementing Vitamin D in Kids if Diet Isn't Enough
Alcohol when to avoid alcohol with certain medications
Medication Errors Follow the Mantra, "When in Doubt, Fill the Incident Report Out"
Supplements the dangers of using dietary supplements
Asthma Spiriva Respimat (tiotropium) will be the first long-acting anticholinergic for ASTHMA

Don't Routinely Recommend Repatha (Evolocumab) for High Cholesterol

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents